BioLine Rx Ltd BLRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BLRX is a good fit for your portfolio.
News
-
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
-
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
-
BioLineRx Announces $6 Million Registered Direct Offering
-
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
-
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
-
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
-
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
-
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.05
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 79
- Website
- https://www.biolinerx.com
Comparables
Valuation
|
Metric
|
BLRX
|
RYTM
|
ITCI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.05 | 13.90 | 11.92 |
Price/Sales | 9.05 | 29.58 | 15.17 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BLRX
|
RYTM
|
ITCI
|
|---|---|---|---|
Quick Ratio | 1.42 | 5.27 | 4.95 |
Current Ratio | 1.53 | 5.58 | 5.41 |
Interest Coverage | −28.21 | −13.26 | — |
Quick Ratio
BLRX
RYTM
ITCI
Profitability
|
Metric
|
BLRX
|
RYTM
|
ITCI
|
|---|---|---|---|
Return on Assets (Normalized) | −62.91% | −46.12% | −13.47% |
Return on Equity (Normalized) | −154.82% | −76.97% | −15.88% |
Return on Invested Capital (Normalized) | −100.04% | −76.40% | −17.96% |
Return on Assets
BLRX
RYTM
ITCI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hlwyhyqd | Rwyw | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mtnrswr | Fldxmpj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vxztvrlh | Ltkmvr | $97.8 Bil | |
MRNA
| Moderna Inc | Xwdbsfstq | Zhkh | $41.3 Bil | |
ARGX
| argenx SE ADR | Qbvxhsjp | Gghn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gvjnvxszk | Cxdt | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jtwsqcpys | Yftpbb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qfqfvnln | Qgfgjsj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wbzxczfcv | Rhyvl | $12.5 Bil | |
INCY
| Incyte Corp | Ltqsysqph | Yqvmhg | $11.6 Bil |